Trial Profile
Phase Ia/Ib trial of ACH 2928 in volunteers and treatment-naive patients with genotype 1 hepatitis C
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 May 2012
Price :
$35
*
At a glance
- Drugs ACH 2928 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 21 Apr 2012 Results assessing monotherapy in patients with genotype 1a or 1b hepatitis C have been presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL-2012) according to an Achillion media release.
- 05 Dec 2011 Preliminary results published in an Achillion Pharmaceuticals media release.
- 11 Jul 2011 Planned number of patients changed to 68, according to information in an Achillion Pharmaceuticals media release.